Skip to main content

Orexigen announces results of phase 3 trial of obesity drug


SAN DIEGO Orexigen Therapeutics said that its phase 3 trial of the drug, Contrave (naltrexone SR/bupropion SR) showed a significant reduction in body weight.

“The results of this trial indicate that additional, clinically significant weight loss can be achieved when Contrave is added to a rigorous program of diet and exercise,” Orexigen CMO Eduardo Dunayevich said in a statement. “We are also very pleased with the safety profile demonstrated by Contrave so far.”

The company plans to submit another approval application for the drug later this year.

This ad will auto-close in 10 seconds